Verification of the Efficacy and Safety of the BAROSTIM NEO System in the Treatment of Drug Resistant Hypertension (NCT01471834)

🧪 Interventions in This Study

• BAROSTIM NEO System (DEVICE)
• Medical Management (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (9 Sites)

• University of Calgary — Calgary, Alberta
• University of Alberta - Edmonton — Edmonton, Alberta
• London-Lawson Health Research Institute — London, Ontario
• University Hospital Cologne — Cologn,
• University Hospital Duesseldorf — Düsseldorf,
• Goettingen-Georg August University — Göttingen,
• Midizinische Hochschule Hannover — Hanover,
• Klinkum St. George Leipzig — Leipzig,
• Maastricht University — Maastricht,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in High Blood Pressure

• Team-Based Home Blood Pressure Monitoring — Rochester, New York
• Salt-Sensitivity and Immunity Cell Activation — Nashville, Tennessee
• STUDY OF THE DOUBLE POLYMORPHISM (THR 555ILE) AND (GLU568PRO) OF THE CORIN GENE AS A RISK FACTOR FOR ARTERIAL HYPERTENSION IN A POPULATION OF AFRICAN DESCENT IN GUADELOUPE — Petit-Bourg,
• Home BP Monitoring — Cleveland, Ohio
• CardioCare Quest: A Co-created Game for Improving Hypertension Treatment Compliance in Arizona — Flagstaff, Arizona

Explore by condition: All High Blood Pressure clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.